Perspective: How will healthcare reform affect cancer care?

Article

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, MD, PhD, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, M.D., Ph.D, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.

Interview: news.cancerconnect.com/asco-2010-how-will-healthcare-reform-affect-cancer-care/

Perspectives and concerns about the affects of Obama-care abound…

On July, 14th the Community Oncology Alliance (COA) announced that due to severe year after year cuts to Medicare reimbursement for cancer care, community oncologists around the US are closing offices at a rate rapidly increasing since January 2010. Reductions in staff, services and facilities are also on the rise.

“As a practicing oncologist, I am extremely concerned about the impact these closings have on
patients. Many are simply falling through the cracks as providers are being forced to cut staff and
close clinics, forcing patients to seek treatments outside of their communities,” said David Eagle,
MD, newly elected President of COA.

--Look here for continuing coverage and analysis of the policies coming from Capitol Hill that directly impact the delivery of oncology services across the country.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.